ClinicalTrials.gg
TerminatedNCT00584779Updated Feb 2, 2021

An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis

A Phase 4 interventional study of Gabapentin and Gabapentin in PK Properties Of Gabapentin In Subjects With Impaired Renal Function, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 1 site in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
See detailed description for termination reason

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Renal Insufficiency with a site in Japan — 1 open to participants now, 3 under way, 1 of them phase 3. Renal Insufficiency · Japan.

Enrollment
28th of 31
8 · median 35
Started
2007
with 1 other
Phase 4
6 of 39
none open now
Registered
6th of 39
by date
Lead sponsor
2 of 39
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 39 studies in Renal Insufficiency with a site in Japan, this one is the 28th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2007, is one of 6 in phase 4, and was the 6th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 39 studies in Renal Insufficiency with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Renal Insufficiency with a site in Japan, or all of them as a file.
02

Study summary

To confirm the pharmacokinetics following administration of gabapentin to Japanese subjects with renal impairment, compare the results to Western study results and confirm the adaptive possibility of dose adjustment in US package insert to Japanese.

Read the detailed description

The study was terminated on September 30, 2008 at the current study site due to reported adverse events in the study subjects (n=8). While the adverse events reported were generally consistent with the known profile of gabapentin, it was decided that the study should continue at a different study site. The pharmacokinetics of gabapentin in the subjects with renal impairment will be evaluated in a separate study with a different study number at a different site. The study will be entitled: "The Pharmacokinetic Study of Gabapentin in Japanese Epileptic Subjects with Renal Impairment".

03

Conditions studied

  • PK Properties Of Gabapentin In Subjects With Impaired Renal Function

Browse trials for

Keywords

  • Gabapentin Pharmacokinetics, renal impairment
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects whose is 5-59 mL/min, or hemodialysis patients.
  • The hemodialysis patients who enter this study is required hemodialysis for at least six weeks (the frequency is three times per week)

Exclusion criteria

Exclusion Criteria:

  • Renal allograft recipients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    1

    Drug: Gabapentin

  • Experimental
    2

    Drug: Gabapentin

  • Experimental
    3

    Drug: Gabapentin

  • Experimental
    4

    Drug: Gabapentin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics

    Time frame: dec 2008

Secondary outcomes

  1. There were no secondary outcomes measures for this study

    Time frame: dec 2008

07

Study locations

1 site
  • Pfizer Investigational Site
    Aira-gun, Aira-cho, Kagoshima-ken, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Jan 2, 2008
Start
Oct 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00584779
Responsible party
Sponsor
First posted
Jan 2, 2008
Start date
Oct 2007
Primary completion
Dec 2007
Completion
Dec 2007
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion